AUS
NZ
UK
CA
USA
IND
Successful MATINEE Trial Results
GSK PLC (LSE:GSK) has announced encouraging results from the Phase III clinical trial named MATINEE, which assessed the efficacy of Nucala (mepolizumab) in treating chronic obstructive pulmonary disease (COPD). The trial successfully met its primary endpoint by demonstrating a statistically significant reduction in the annualized rate of moderate to severe exacerbations among patients administered Nucala compared to those receiving a placebo.
Trial Details and Patient Profile
The MATINEE trial involved patients with chronic bronchitis or emphysema, who were also undergoing optimized inhaled maintenance therapy. These patients had elevated blood eosinophil counts, which serve as a biomarker for type 2 inflammation associated with COPD exacerbations. Treatment in the study extended up to 104 weeks, and preliminary safety results were consistent with the known safety profile of Nucala.
Future Steps and Regulatory Considerations
Full results from the MATINEE trial are slated to be presented at an upcoming scientific congress. These results will play a crucial role in discussions with regulatory authorities. It is important to note that, at present, Nucala is not approved for use in COPD in any country. The outcomes of this trial could have significant implications for the drug's future approval and use in treating this condition.
